{"text_format":"3","workbook":"xlsx","n_sheets":7,"sheets":["P&L","Balance Sheet","Cash Flow","Net Income & EPS Non-GAAP","Segment Results","Core Revenue by Segment (QTD)","Core Revenue by Segment (YTD)"],"not_rendered":{"defined_names":25},"read":"whole","date_system":"1900"}

{"sheet":"P&L","index":0,"n_rows":51,"n_cols":8,"rows_kept":51,"merged":[[0,0,0,7],[1,0,1,7],[2,0,2,7],[3,0,3,7],[4,0,4,7],[7,1,7,3],[7,5,7,7],[8,1,8,3],[8,5,8,7],[47,0,47,7],[50,0,50,7],[53,0,53,5]]}
["AGILENT TECHNOLOGIES, INC."]
["CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS"]
["(In millions, except per share amounts)"]
["(Unaudited)"]
["PRELIMINARY"]
[]
[]
[null,"Three Months Ended",{"$nulls":3},"Years Ended"]
[null,"January 31,",{"$nulls":3},"October 31, "]
[null,2024,null,2023,null,2024,null,2023]
[]
["Net revenue",{"v":1658,"d":"$1,658"},null,{"v":1756,"d":"$1,756"},{"$nulls":3},{"v":6833,"d":"$6,833"}]
[]
["Costs and expenses:"]
["Cost of products and services",750,null,788,{"$nulls":3},{"v":3368,"d":"3,368"}]
["Research and development",128,null,123,{"$nulls":3},481]
["Selling, general and administrative",396,null,419,{"$nulls":3},{"v":1634,"d":"1,634"}]
["Total costs and expenses",{"$f":"SUM(B15:B17)","v":{"v":1274,"d":"1,274"}},null,{"$f":"SUM(D15:D17)","v":{"v":1330,"d":"1,330"}},null,{"$f":"SUM(F15:F17)","v":0},null,{"$f":"SUM(H15:H17)","v":{"v":5483,"d":"5,483"}}]
[]
["Income from operations",{"$f":"B12-B18","v":384},null,{"$f":"D12-D18","v":426},null,{"$f":"F12-F18","v":0},null,{"$f":"H12-H18","v":{"v":1350,"d":"1,350"}}]
[]
["Interest income",18,null,9,{"$nulls":3},51]
["Interest expense",{"v":-22,"d":"(22)"},null,{"v":-25,"d":"(25)"},{"$nulls":3},{"v":-95,"d":"(95)"}]
["Other income (expense), net",23,null,"—",{"$nulls":3},33]
[]
["Income before taxes",{"$f":"SUM(B20:B24)","v":403},null,{"$f":"SUM(D20:D24)","v":410},null,{"$f":"SUM(F20:F24)","v":0},null,{"$f":"SUM(H20:H24)","v":{"v":1339,"d":"1,339"}}]
[]
["Provision for income taxes",55,null,58,{"$nulls":3},99]
[]
["Net income ",{"$f":"B26-B28","v":{"v":348,"d":"$348"}},null,{"$f":"D26-D28","v":{"v":352,"d":"$352"}},null,{"$f":"F26-F28","v":0},null,{"$f":"H26-H28","v":{"v":1240,"d":"$1,240"}}]
[]
[]
[]
["Net income per share:"]
["                             Basic",{"$f":"B30/B39","v":{"v":1.1877133105802047,"d":"$1.19"}},null,{"$f":"D30/D39","v":{"v":1.1891891891891893,"d":"$1.19"}},null,{"$f":"F30/F39","v":{"$error":"#DIV/0!"}},null,{"$f":"H30/H39","v":{"v":4.217687074829932,"d":"$4.22"}}]
["                             Diluted",{"$f":"B30/B40","v":{"v":1.183673469387755,"d":"$1.18"}},null,{"$f":"D30/D40","v":{"v":1.1851851851851851,"d":"$1.19"}},null,{"$f":"F30/F40","v":{"$error":"#DIV/0!"}},null,{"$f":"H30/H40","v":{"v":4.1891891891891895,"d":"$4.19"}}]
[]
["Weighted average shares used in computing net income per share:     "]
["                             Basic",293,null,296,{"$nulls":3},294]
["                             Diluted",294,null,297,{"$nulls":3},296]
{"$rows_empty":7}
["The preliminary income statement is estimated based on our current information."]
[]
[]
["Page 1"]

{"sheet":"Balance Sheet","index":1,"n_rows":60,"n_cols":7,"rows_kept":60,"merged":[[0,0,0,6],[1,0,1,6],[2,0,2,6],[3,0,3,6],[4,0,4,6],[59,0,59,6]]}
["AGILENT TECHNOLOGIES, INC."]
["CONDENSED CONSOLIDATED BALANCE SHEET"]
["(In millions, except par value and share data)"]
["(Unaudited)"]
["PRELIMINARY"]
[]
[]
[{"$nulls":4},"January 31,",null,"October 31,"]
[{"$nulls":4},2024,null,2023]
["ASSETS"]
[]
["Current assets:"]
[null,"Cash and cash equivalents",null,null,{"v":1748,"d":"$1,748"},null,{"v":1590,"d":"$1,590"}]
[null,"Short-term investments"]
[null,"Accounts receivable, net",null,null,{"v":1295,"d":"1,295"},null,{"v":1291,"d":"1,291"}]
[null,"Inventory",null,null,{"v":1033,"d":"1,033"},null,{"v":1031,"d":"1,031"}]
[null,"Other current assets",null,null,262,null,274]
[null,null,"Total current assets",null,{"$f":"SUM(E13:E17)","v":{"v":4338,"d":"4,338"}},null,{"$f":"SUM(G13:G17)","v":{"v":4186,"d":"4,186"}}]
[]
["Property, plant and equipment, net",{"$nulls":3},{"v":1314,"d":"1,314"},null,{"v":1270,"d":"1,270"}]
["Goodwill",{"$nulls":3},{"v":3967,"d":"3,967"},null,{"v":3960,"d":"3,960"}]
["Other intangible assets, net",{"$nulls":3},443,null,475]
["Long-term investments",{"$nulls":3},170,null,164]
["Other assets",{"$nulls":3},716,null,708]
[null,null,"Total assets",null,{"$f":"SUM(E18:E24)","v":{"v":10948,"d":"$10,948"}},null,{"$f":"SUM(G18:G24)","v":{"v":10763,"d":"$10,763"}}]
[]
["LIABILITIES AND EQUITY"]
[]
["Current liabilities:"]
[null,"Accounts payable",null,null,{"v":488,"d":"$488"},null,{"v":418,"d":"$418"}]
[null,"Employee compensation and benefits",null,null,272,null,371]
[null,"Deferred revenue",null,null,522,null,505]
[null,"Short-term debt",null,null,"—  ",null,"—  "]
[null,"Other accrued liabilities",null,null,335,null,309]
[null,null,"Total current liabilities",null,{"$f":"SUM(E30:E34)","v":{"v":1617,"d":"1,617"}},null,{"$f":"SUM(G30:G34)","v":{"v":1603,"d":"1,603"}}]
[]
["Long-term debt",{"$nulls":3},{"v":2555,"d":"2,555"},null,{"v":2735,"d":"2,735"}]
["Retirement and post-retirement benefits",{"$nulls":3},102,null,103]
["Other long-term liabilities",{"$nulls":3},486,null,477]
[null,null,"Total liabilities",null,{"$f":"SUM(E35:E39)","v":{"v":4760,"d":"4,760"}},null,{"$f":"SUM(G35:G39)","v":{"v":4918,"d":"4,918"}}]
[]
["Total Equity:"]
[null,"Stockholders' equity:"]
[null,"Preferred stock; $0.01 par value; 125,000,000"]
[null,null,"shares authorized; none issued and outstanding at January 31, 2024 and October 31, 2023",null,"—  ",null,"—  "]
[null,"Common stock; $0.01 par value, 2,000,000,000"]
[null,null,"shares authorized; 293,041,817 shares at January 31, 2024"]
[null,null,"and 292,123,241 shares at October 31, 2023, issued and outstanding",null,3,null,3]
[null,"Additional paid-in-capital",null,null,{"v":5440,"d":"5,440"},null,{"v":5387,"d":"5,387"}]
[null,"Retained earnings",null,null,{"v":1061,"d":"1,061"},null,782]
[null,"Accumulated other comprehensive loss",null,null,{"v":-316,"d":"(316)"},null,{"v":-327,"d":"(327)"}]
[null,null,"Total stockholders' equity",null,{"$f":"SUM(E45:E51)","v":{"v":6188,"d":"6,188"}},null,{"$f":"SUM(G45:G51)","v":{"v":5845,"d":"5,845"}}]
[{"$nulls":3},"Total liabilities and stockholders' equity",{"$f":"E40+E52","v":{"v":10948,"d":"$10,948"}},null,{"$f":"G40+G52","v":{"v":10763,"d":"$10,763"}}]
[]
[]
["The preliminary balance sheet is estimated based on our current information."]
[]
[]
[]
["Page 2"]

{"sheet":"Cash Flow","index":2,"n_rows":78,"n_cols":8,"rows_kept":78,"merged":[[0,0,0,7],[1,0,1,7],[2,0,2,7],[3,0,3,7],[4,0,4,7],[7,5,7,7],[77,0,77,7]]}
["AGILENT TECHNOLOGIES, INC."]
["CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS"]
["(In millions)"]
["(Unaudited)"]
["PRELIMINARY"]
[]
[]
[{"$nulls":5},"Three Months Ended"]
[{"$nulls":5},"January 31,",null,{"$f":"F9","v":"January 31,"}]
[{"$nulls":5},2024,null,2023]
["Cash flows from operating activities:"]
[null,"Net income",{"$nulls":3},{"v":348,"d":"$348"},null,{"v":352,"d":"$352"}]
[]
["Adjustments to reconcile net income to net cash provided by operating activities:"]
[null,"Depreciation and amortization",{"$nulls":3},62,null,67]
[null,"Share-based compensation",{"$nulls":3},44,null,44]
[null,"Deferred taxes",{"$nulls":3},"—  ",null,4]
[null,"Excess and obsolete inventory related charges",{"$nulls":3},11,null,7]
[null,"Net (gain) loss on equity securities",{"$nulls":3},{"v":-3,"d":"(3)"},null,10]
[null,"Asset impairment charges",{"$nulls":3},8,null,"—  "]
[null,"Change in fair value of contingent consideration",{"$nulls":3},"—  ",null,1]
[null,"Loss on extinguishment of debt",{"$nulls":3},"—  ",null,"—  "]
[null,"Other non-cash (income) expense, net",{"$nulls":3},{"v":-6,"d":"(6)"},null,1]
[null,"Changes in assets and liabilities:"]
[null,null,"Accounts receivable, net",null,null,10,null,{"v":-5,"d":"(5)"}]
[null,null,"Inventory",null,null,{"v":-9,"d":"(9)"},null,{"v":-69,"d":"(69)"}]
[null,null,"Accounts payable",null,null,84,null,{"v":-27,"d":"(27)"}]
[null,null,"Employee compensation and benefits",null,null,{"v":-104,"d":"(104)"},null,{"v":-174,"d":"(174)"}]
[null,null,"Other assets and liabilities ",null,null,40,null,85]
["Net cash provided by operating activities (a)",{"$nulls":4},{"$f":"SUM(F12:F29)","v":485},null,{"$f":"SUM(H12:H29)","v":296}]
[]
["Cash flows from investing activities:"]
[null,"Payments to acquire property, plant and equipment",{"$nulls":3},{"v":-90,"d":"(90)"},null,{"v":-76,"d":"(76)"}]
[null,"Proceeds from sale of equity securities",{"$nulls":3},"—  ",null,4]
[null,"Payments to acquire equity securities",{"$nulls":3},"—  ",null,{"v":-1,"d":"(1)"}]
[null,"Proceeds from convertible note",{"$nulls":3},"—  ",null,2]
[null,"Payments in exchange for convertible note",{"$nulls":3},{"v":-5,"d":"(5)"},null,{"v":-3,"d":"(3)"}]
[null,"Proceeds from divestiture of business",{"$nulls":3},"—  ",null,"—  "]
[null,"Payments to acquire businesses and intangible assets, net of cash acquired",{"$nulls":3},"—  ",null,{"v":-30,"d":"(30)"}]
["Net cash used in investing activities",{"$nulls":4},{"$f":"SUM(F33:F39)","v":{"v":-95,"d":"(95)"}},null,{"$f":"SUM(H33:H39)","v":{"v":-104,"d":"(104)"}}]
[]
["Cash flows from financing activities:"]
[null,"Proceeds from issuance of common stock under employee stock plans",{"$nulls":3},34,null,35]
[null,"Payment of taxes related to net share settlement of equity awards ",{"$nulls":3},{"v":-25,"d":"(25)"},null,{"v":-51,"d":"(51)"}]
[null,"Payments for repurchase of common stock",{"$nulls":3},"—  ",null,{"v":-75,"d":"(75)"}]
[null,"Payments of dividends",{"$nulls":3},{"v":-69,"d":"(69)"},null,{"v":-67,"d":"(67)"}]
[null,"Repayments of long-term debt",{"$nulls":3},{"v":-180,"d":"(180)"},null,"—  "]
[null,"Net proceeds from short-term debt",{"$nulls":3},"—  ",null,203]
[null,"Payment for contingent consideration",{"$nulls":3},"—  ",null,{"v":-62,"d":"(62)"}]
["Net cash used in financing activities",{"$nulls":4},{"$f":"SUM(F41:F49)","v":{"v":-240,"d":"(240)"}},null,{"$f":"SUM(H41:H49)","v":{"v":-17,"d":"(17)"}}]
[]
["Effect of exchange rate movements",{"$nulls":4},7,null,22]
[]
["Net increase in cash, cash equivalents and restricted cash",{"$nulls":4},{"$f":"F30+F40+F50+F52","v":157},null,{"$f":"H30+H40+H50+H52","v":197}]
[]
["Cash, cash equivalents and restricted cash at beginning of period",{"$nulls":4},{"v":1593,"d":"1,593"},null,{"v":1056,"d":"1,056"}]
[]
["Cash, cash equivalents and restricted cash at end of period",{"$nulls":4},{"$f":"SUM(F54:F56)","v":{"v":1750,"d":"$1,750"}},null,{"$f":"SUM(H54:H56)","v":{"v":1253,"d":"$1,253"}}]
[]
[]
["Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet:"]
[]
[null,"Cash and cash equivalents",{"$nulls":3},{"v":1748,"d":"$1,748"},null,{"v":1250,"d":"$1,250"}]
[null,"Restricted cash, included in other assets",{"$nulls":3},2,null,3]
[null,"Total cash, cash equivalents and restricted cash",{"$nulls":3},{"$f":"SUM(F63:F64)","v":{"v":1750,"d":"$1,750"}},null,{"$f":"SUM(H63:H64)","v":{"v":1253,"d":"$1,253"}}]
[]
[]
["(a) Cash payments included in operating activities:"]
[]
[null,"Income tax paid, net of refunds received",{"$nulls":3},{"v":24,"d":"$24"},null,{"v":17,"d":"$17"}]
[null,"Interest payments, net of capitalized interest",{"$nulls":3},{"v":14,"d":"$14"},null,{"v":15,"d":"$15"}]
[]
[]
[]
["The preliminary cash flow is estimated based on our current information."]
[]
[]
["Page 3"]

{"sheet":"Net Income & EPS Non-GAAP","index":3,"n_rows":49,"n_cols":15,"rows_kept":49,"merged":[[0,0,0,15],[1,0,1,15],[2,0,2,15],[3,0,3,15],[4,0,4,15],[6,4,6,8],[6,10,6,14],[7,4,7,8],[7,10,7,14],[8,4,8,5],[8,7,8,8],[8,10,8,11],[8,13,8,14],[10,13,10,14],[25,0,25,14],[26,0,26,14],[27,1,27,14],[28,1,28,14],[29,1,29,14],[30,1,30,14],[31,1,31,14],[32,1,32,14],[33,1,33,14],[34,1,34,14],[35,1,35,14],[36,1,36,14],[36,15,36,28],[36,29,36,31],[37,1,37,14],[39,0,39,14],[41,0,41,14],[43,0,43,14],[46,0,46,14],[48,0,48,14]]}
["AGILENT TECHNOLOGIES, INC."]
["NON-GAAP NET INCOME AND DILUTED EPS RECONCILIATIONS"]
["(In millions, except per share amounts)"]
["(Unaudited)"]
["PRELIMINARY"]
[]
[{"$nulls":4},"Three Months Ended",{"$nulls":5},"Years Ended"]
[{"$nulls":4},"January 31,",{"$nulls":5},{"$f":"E8","v":"January 31,"}]
[{"$nulls":4},2024,null,null,2023,null,null,2023,null,null,2022]
[{"$nulls":4},"Net Income","Diluted EPS",null,"Net Income","Diluted EPS",null,"Net Income","Diluted EPS",null,"Net Income","Diluted EPS"]
[]
["GAAP net income",{"$nulls":3},{"v":348,"d":"$348"},{"v":1.18,"d":"$1.18"},null,{"v":352,"d":"$352"},{"v":1.19,"d":"$1.19"},null,{"v":1240,"d":"$1,240"},{"v":4.19,"d":"$4.19"},null,{"v":1254,"d":"$1,254"},{"v":4.18,"d":"$4.18"}]
[null,"Non-GAAP adjustments:"]
[null,null,"Restructuring and other related costs",null,3,0.01,null,"—","—",null,46,0.16,null,"—","—"]
[null,null,"Asset impairments",null,8,0.03,null,"—","—"]
[null,null,"Intangible amortization",null,26,0.09,null,36,0.12,null,139,0.47,null,191,0.64]
[null,null,"Transformational initiatives",null,3,0.01,null,7,0.02,null,25,0.08,null,30,{"v":0.1,"d":"0.10"}]
[null,null,"Acquisition and integration costs",null,2,0.01,null,2,0.01,null,16,0.05,null,25,0.08]
[null,null,"Net loss on equity securities",null,"—","—",null,12,0.04,null,42,0.14,null,63,0.21]
[null,null,"Change in fair value of contingent consideration",null,"—","—",null,1,"—",null,1,"—",null,{"v":-25,"d":"(25)"},{"v":-0.08,"d":"(0.08)"}]
[null,null,"Other",null,{"v":-6,"d":"(6)"},{"v":-0.02,"d":"(0.02)"},null,3,0.01,null,11,0.04,null,12,0.04]
[null,null,"Adjustment for taxes (a)",null,{"v":-4,"d":"(4)"},{"v":-0.02,"d":"(0.02)"},null,{"v":-7,"d":"(7)"},{"v":-0.02,"d":"(0.02)"},null,{"v":-158,"d":"(158)"},{"v":-0.52,"d":"(0.52)"},null,{"v":-5,"d":"(5)"},{"v":-0.01,"d":"(0.01)"}]
["Non-GAAP net income",{"$nulls":3},{"$f":"SUM(E12:E22)","v":{"v":380,"d":"$380"}},{"$f":"SUM(F12:F22)","v":{"v":1.29,"d":"$1.29"}},null,{"$f":"SUM(H12:H22)","v":{"v":406,"d":"$406"}},{"$f":"SUM(I12:I22)","v":{"v":1.37,"d":"$1.37"}},null,{"$f":"SUM(K12:K22)","v":{"v":1362,"d":"$1,362"}},{"$f":"SUM(L12:L22)","v":{"v":4.609999999999999,"d":"$4.61"}},null,{"$f":"SUM(N12:N22)","v":{"v":1545,"d":"$1,545"}},{"$f":"SUM(O12:O22)","v":{"v":5.159999999999999,"d":"$5.16"}}]
[]
[]
["(a) The adjustment for taxes excludes tax expense (benefits) that management believes are not directly related to on-going operations and which are either isolated, temporary or cannot be expected to occur again with any regularity or predictability such as the realized gain/loss due to sale of a business, windfall benefits on stock compensation, and the impact of R&D capitalization under section 174 of the Tax Cuts and Jobs Act of 2017.  For the three months ended January 31, 2024, management used a non-GAAP effective tax rate of 13.50%.  For the three months ended January 31, 2023, management used a non-GAAP effective tax rate of 13.75%.  "]
["We provide non-GAAP net income and non-GAAP net income per share amounts in order to provide meaningful supplemental information regarding our operational performance and our prospects for the future. These supplemental measures exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, net loss on equity securities and change in fair value of contingent consideration."]
[null,"Restructuring and other related costs include incremental expenses incurred in the period associated with restructuring programs, usually aimed at changes in business and/or cost structure. Such costs may include one-time termination benefits, facility-related costs and contract termination fees. "]
[null,"Asset impairments include assets that have been written down to their fair value."]
[null,"Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers including costs to move manufacturing, small site consolidations, legal entity and other business reorganizations, insourcing or outsourcing of activities. Such costs may include move and relocation costs, one-time termination benefits and other one-time reorganization costs. Included in this category are also expenses associated with company programs to transform our product lifecycle management (PLM) system, human resources and financial systems.\n\n"]
[null,"Acquisition and integration costs include all incremental expenses incurred to effect a business combination. Such acquisition costs may include advisory, legal, accounting, valuation, and other professional or consulting fees. Such integration costs may include expenses directly related to integration of business and facility operations, the transfer of assets and intellectual property, information technology systems and infrastructure and other employee-related costs. \n"]
[null,"Business exit and divestiture costs (gain) include costs and gain associated with business divestitures. "]
[null,"Net loss on equity securities relates to the realized and unrealized mark-to-market adjustments for our marketable and non-marketable equity securities."]
[null,"Special compliance costs include costs associated with transforming our processes to implement new regulations such as environmental compliance costs related to a prior acquisition, NASD site costs and certain tax reporting requirements."]
[null,"Change in fair value of contingent consideration represents changes in the fair value estimate of acquisition-related contingent consideration."]
[null,"NASD site costs include all the costs related to the expansion of our manufacturing of nucleic acid active pharmaceutical ingredients incurred prior to the commencement of commercial manufacturing. "]
[null,"Other includes acceleration of share-based compensation expense and certain legal costs and settlements in addition to other miscellaneous adjustments."]
[null,"Tax benefit on intra-entity asset transfer relates to our operations in Singapore along with our application of the new accounting rules for income tax consequences of intra-entity transfer of assets as adopted on November 1, 2018."]
[]
["Our management uses non-GAAP measures to evaluate the performance of our core businesses, to estimate future core performance and to compensate employees. Since management finds this measure to be useful, we believe that our investors benefit from seeing our results “through the eyes” of management in addition to seeing our GAAP results. This information facilitates our management’s internal comparisons to our historical operating results as well as to the operating results of our competitors."]
[]
["Our management recognizes that items such as amortization of intangibles can have a material impact on our cash flows and/or our net income. Our GAAP financial statements including our statement of cash flows portray those effects. Although we believe it is useful for investors to see core performance free of special items, investors should understand that the excluded items are actual expenses that may impact the cash available to us for other uses. To gain a complete picture of all effects on the company’s profit and loss from any and all events, management does (and investors should) rely upon the GAAP income statement. The non-GAAP numbers focus instead upon the core business of the company, which is only a subset, albeit a critical one, of the company’s performance."]
[]
["Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies."]
[]
["The preliminary non-GAAP net income and diluted EPS reconciliation is estimated based on our current information."]
[]
[]
["Page 4"]

{"sheet":"Segment Results","index":4,"n_rows":68,"n_cols":5,"rows_kept":68,"merged":[[0,0,0,4],[0,5,0,8],[1,0,1,4],[2,0,2,4],[3,0,3,4],[4,0,4,4],[7,0,7,4],[33,0,33,4],[60,0,60,4],[62,0,62,4],[67,0,67,4]]}
["AGILENT TECHNOLOGIES, INC."]
["SEGMENT INFORMATION"]
["(In millions, except where noted)"]
["(Unaudited)"]
["PRELIMINARY"]
[]
[]
["Quarter-over-Quarter"]
[]
["Life Sciences and Applied Markets Group"]
[null,null,"Q1'24",null,"Q1'23"]
["Revenue",null,{"v":846,"d":"$846"},null,{"v":943,"d":"$943"}]
["Gross Margin, %",null,{"v":0.602,"d":"60.2%"},null,{"v":0.615,"d":"61.5%"}]
["Income from Operations",null,{"v":236,"d":"$236"},null,{"v":300,"d":"$300"}]
["Operating margin, %",null,{"v":0.279,"d":"27.9%"},null,{"v":0.318,"d":"31.8%"}]
[]
[]
["Diagnostics and Genomics Group"]
[null,null,{"$f":"C11","v":"Q1'24"},null,{"$f":"E11","v":"Q1'23"}]
["Revenue",null,{"v":407,"d":"$407"},null,{"v":432,"d":"$432"}]
["Gross Margin, %",null,{"v":0.528,"d":"52.8%"},null,{"v":0.526,"d":"52.6%"}]
["Income from Operations",null,{"v":70,"d":"$70"},null,{"v":73,"d":"$73"}]
["Operating margin, %",null,{"v":0.173,"d":"17.3%"},null,{"v":0.169,"d":"16.9%"}]
[]
[]
["Agilent CrossLab Group"]
[null,null,{"$f":"C11","v":"Q1'24"},null,{"$f":"E11","v":"Q1'23"}]
["Revenue",null,{"v":405,"d":"$405"},null,{"v":381,"d":"$381"}]
["Gross Margin, %",null,{"v":0.505,"d":"50.5%"},null,{"v":0.485,"d":"48.5%"}]
["Income from Operations",null,{"v":122,"d":"$122"},null,{"v":103,"d":"$103"}]
["Operating margin, %",null,{"v":0.302,"d":"30.2%"},null,{"v":0.27,"d":"27.0%"}]
[]
[]
["Year-over-Year"]
[]
["Life Sciences and Applied Markets Group"]
[null,null,"FY24",null,"FY23"]
["Revenue",{"$nulls":3},{"v":3856,"d":"$3,856"}]
["Gross Margin, %",{"$nulls":3},{"v":0.602,"d":"60.2%"}]
["Income from Operations",{"$nulls":3},{"v":1116,"d":"$1,116"}]
["Operating margin, %",{"$nulls":3},{"v":0.289,"d":"28.9%"}]
[]
[]
["Diagnostics and Genomics Group"]
[null,null,{"$f":"C37","v":"FY24"},null,{"$f":"E37","v":"FY23"}]
["Revenue",{"$nulls":3},{"v":1409,"d":"$1,409"}]
["Gross Margin, %",{"$nulls":3},{"v":0.518,"d":"51.8%"}]
["Income from Operations",{"$nulls":3},{"v":296,"d":"$296"}]
["Operating margin, %",{"$nulls":3},{"v":0.21,"d":"21.0%"}]
[]
[]
["Agilent CrossLab Group"]
[null,null,{"$f":"C37","v":"FY24"},null,{"$f":"E37","v":"FY23"}]
["Revenue",{"$nulls":3},{"v":1568,"d":"$1,568"}]
["Gross Margin, %",{"$nulls":3},{"v":0.493,"d":"49.3%"}]
["Income from Operations",{"$nulls":3},{"v":463,"d":"$463"}]
["Operating margin, %",{"$nulls":3},{"v":0.295,"d":"29.5%"}]
[]
[]
[]
["Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs and change in fair value of contingent consideration."]
[]
["Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures.  They should be read in conjunction with the GAAP financial measures.  It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies."]
[]
["The preliminary segment information is estimated based on our current information. "]
[]
[]
["Page 5"]

{"sheet":"Core Revenue by Segment (QTD)","index":5,"n_rows":45,"n_cols":9,"rows_kept":45,"merged":[[0,0,0,8],[1,0,1,8],[2,0,2,8],[3,0,3,8],[4,0,4,8],[5,0,5,8],[7,1,7,8],[9,1,9,3],[21,1,21,3],[21,5,21,6],[22,6,23,6],[22,8,23,8],[32,0,32,8],[34,0,34,8],[36,0,36,8],[38,0,38,8],[41,0,41,8],[44,0,44,8]]}
["AGILENT TECHNOLOGIES, INC."]
["RECONCILIATIONS OF REVENUE BY SEGMENT"]
["EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)"]
["(in millions)"]
["(Unaudited)"]
["PRELIMINARY"]
[]
[null,"Year-over-Year"]
[]
[null,"GAAP"]
[{"$nulls":3},"Year-over-Year"]
["GAAP Revenue by Segment","Q1'24","Q1'23","% Change"]
[]
["Life Sciences and Applied Markets Group",{"v":846,"d":"$846"},{"v":943,"d":"$943"},{"v":-0.1,"d":"(10%)"}]
["Diagnostics and Genomics Group",407,432,{"v":-0.06,"d":"(6%)"}]
["Agilent CrossLab Group",405,381,{"v":0.06,"d":"6%"}]
["Agilent",{"$f":"SUM(B14:B16)","v":{"v":1658,"d":"$1,658"}},{"$f":"SUM(C14:C16)","v":{"v":1756,"d":"$1,756"}},{"v":-0.06,"d":"(6%)"}]
[]
[]
[]
[]
[null,"Non-GAAP \n(excluding Acquisitions & Divestitures)",{"$nulls":3},"Year-over-Year\nat Constant Currency (a)"]
[{"$nulls":3},"Year-over-Year",null,"Year-over-Year","Percentage Point Impact from Currency",null,"Current Quarter Currency Impact (b)"]
["Non GAAP Revenue by Segment",{"$f":"B12","v":"Q1'24"},{"$f":"C12","v":"Q1'23"},"% Change",null,"% Change"]
[]
["Life Sciences and Applied Markets Group",{"v":846,"d":"$846"},{"v":943,"d":"$943"},{"v":-0.1,"d":"(10%)"},null,{"v":-0.11,"d":"(11%)"},"1 ppt",null,{"v":7,"d":"$7"}]
["Diagnostics and Genomics Group ",407,430,{"v":-0.05,"d":"(5%)"},null,{"v":-0.06,"d":"(6%)"},"1 ppt",null,4]
["Agilent CrossLab Group ",405,381,{"v":0.06,"d":"6%"},null,{"v":0.05,"d":"5%"},"1 ppt",null,5]
["Agilent (Core)",{"$f":"SUM(B26:B28)","v":{"v":1658,"d":"$1,658"}},{"$f":"SUM(C26:C28)","v":{"v":1754,"d":"$1,754"}},{"v":-0.05,"d":"(5%)"},null,{"v":-0.06,"d":"(6%)"},"1 ppt",null,{"$f":"SUM(I26:I28)","v":{"v":16,"d":"$16"}}]
[]
[]
[]
["We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.  "]
[]
["(a) The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change."]
[]
["(b) The dollar impact from the current quarter currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change."]
[]
["The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information."]
[]
[]
[]
[]
[]
["Page 6"]

{"sheet":"Core Revenue by Segment (YTD)","index":6,"n_rows":45,"n_cols":9,"rows_kept":45,"hidden":true,"merged":[[0,0,0,8],[1,0,1,8],[2,0,2,8],[3,0,3,8],[4,0,4,8],[5,0,5,8],[7,1,7,8],[9,1,9,3],[21,1,21,3],[21,5,21,6],[22,6,23,6],[22,8,23,8],[32,0,32,8],[34,0,34,8],[36,0,36,8],[38,0,38,8],[41,0,41,8],[44,0,44,8]]}
["AGILENT TECHNOLOGIES, INC."]
["RECONCILIATIONS OF REVENUE BY SEGMENT"]
["EXCLUDING ACQUISITIONS, DIVESTITURES AND THE IMPACT OF CURRENCY ADJUSTMENTS (CORE)"]
["(in millions)"]
["(Unaudited)"]
["PRELIMINARY"]
[]
[null,"Year-over-Year"]
[]
[null,"GAAP"]
[{"$nulls":3},"Year-over-Year"]
["GAAP Revenue by Segment","FY24","FY23","% Change"]
[]
["Life Sciences and Applied Markets Group"]
["Diagnostics and Genomics Group"]
["Agilent CrossLab Group"]
["Agilent",{"$f":"SUM(B14:B16)","v":0},{"$f":"SUM(C14:C16)","v":0}]
[]
[]
[]
[]
[null,"Non-GAAP \n(excluding Acquisitions & Divestitures)",{"$nulls":3},"Year-over-Year\nat Constant Currency (a)"]
[{"$nulls":3},"Year-over-Year",null,"Year-over-Year","Percentage Point Impact from Currency",null,"Current Quarter Currency Impact (b)"]
["Non GAAP Revenue by Segment",{"$f":"B12","v":"FY24"},{"$f":"C12","v":"FY23"},"% Change",null,"% Change"]
[]
["Life Sciences and Applied Markets Group"]
["Diagnostics and Genomics Group "]
["Agilent CrossLab Group "]
["Agilent (Core)",{"$f":"SUM(B26:B28)","v":0},{"$f":"SUM(C26:C28)","v":0},{"$nulls":5},{"$f":"SUM(I26:I28)","v":0}]
[]
[]
[]
["We compare the year-over-year change in revenue excluding the effect of recent acquisitions and divestitures and foreign currency rate fluctuations to assess the performance of our underlying business.  "]
[]
["(a) The constant currency year-over-year growth percentage is calculated by recalculating all periods in the comparison period at the foreign currency exchange rates used for accounting during the last month of the current quarter and then using those revised values to calculate the year-over-year percentage change."]
[]
["(b) The dollar impact from the current year currency impact is equal to the total year-over-year dollar change less the constant currency year-over-year change."]
[]
["The preliminary reconciliation of GAAP revenue adjusted for recent acquisitions and divestitures and impact of currency is estimated based on our current information."]
[]
[]
[]
[]
[]
["Page 7"]